Zobrazeno 61 - 70
of 303
pro vyhledávání: '"Benoit You"'
Autor:
Olivier Tredan, Romaine Mayet, Magali Morelle, Benoit You, François Parant, Marine Villard, Isabelle Ray-Coquard, Thomas Bachelot, Sébastien Viel, David Pérol, Emily Charrier, Yamila Rocca, Gwenaële Garin, Antoine Marçais, Laurie Besson, Pierre Heudel, Thierry Walzer, Benoîte Méry
Publikováno v:
Journal of Immunology
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2021, 206 (10), pp.2265-2270. ⟨10.4049/jimmunol.2001215⟩
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2021, 206 (10), pp.2265-2270. ⟨10.4049/jimmunol.2001215⟩
NK cells are cytotoxic lymphocytes displaying strong antimetastatic activity. Mouse models and in vitro studies suggest a prominent role of the mechanistic target of rapamycin (mTOR) kinase in the control of NK cell homeostasis and antitumor function
Autor:
Pascal, Pujol, Kevin, Yauy, Amandine, Coffy, Nicolas, Duforet-Frebourg, Sana, Gabteni, Jean-Pierre, Daurès, Frédérique, Penault Llorca, Frédéric, Thomas, Kevin, Hughes, Clare, Turnbull, Virginie, Galibert, Chloé, Rideau, Carole, Corsini, Laetitia, Collet, Benoit, You, David, Geneviève, Nicolas, Philippe
Publikováno v:
Cancers. 14(13)
Poly(ADP-ribose) polymerase 1 inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer who carry a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA) in both the metastatic and adjuvant settin
Autor:
Tifenn Lharidon, J C Théry, Marie-Ange Mouret Reynier, Philippe Barthélémy, Thomas Filleron, Francesco Del Piano, Marc Debled, Christelle Levy, Monica Arnedos, Alexandra Jacquet, Xavier Tchiknavorian, Florence Dalenc, Alicia Tran-Dien, Anthony Gonçalves, Jean-Marc Ferrero, Fabrice Andre, Mario Campone, Ivan Bièche, Benjamin Verret, Ingrid Garberis, Amélie Lusque, Florence Coussy, Etienne Rouleau, C. Lefeuvre-Plesse, Marie-Paule Sablin, Alice Mege, Marta Jimenez, William Jacot, Benoit You, Thomas Bachelot, Nicolas Isambert, Julien Adam
Publikováno v:
Nature Medicine. 27:250-255
The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor recep
Autor:
J. Grenier, Isabelle Moullet, Jérôme Meunier, Brigitte Lucas, Raymond Despax, Adina Marti, Jean-Marc Ferrero, Fabien Brocard, Alain Lortholary, Benoit You, A.M. Savoye, Jérôme Martin-Babau, Anne-Claire Hardy-Bessard, Florian Clatot, George Emile
Publikováno v:
Breast, Vol 54, Iss, Pp 256-263 (2020)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Purpose Combining bevacizumab with paclitaxel significantly improves progression-free survival (PFS) versus paclitaxel alone in HER2-negative metastatic breast cancer (MBC). Eribulin is active and tolerable in pretreated MBC. To assess whether eribul
Autor:
Emma V. Jones, Joon Rhee, Jérôme Alexandre, Zhongwu Lai, L Opincar, Matthew G Krebs, Yeon Hee Park, Jean Pierre Delord, Antoine Italiano, Anna M. L. Coenen-Stass, Seock-Ah Im, Sara Bastian, Sophie Postel-Vinay, Sakshi Gulati, Susan M. Domchek, Ding Wang, Saiama N. Waqar, Haiyan Gao, Benoit You, P. Herbolsheimer, M. Lanasa, Helen K. Angell, Iwanka Kozarewa, Vidalba Rocher-Ros, Bella Kaufman
Publikováno v:
Domchek, S M, Postel-Vinay, S, Im, S-A, Park, Y H, Delord, J-P, Italiano, A, Alexandre, J, You, B, Bastian, S, Krebs, M G, Wang, D, Waqar, S N, Lanasa, M, Rhee, J, Gao, H, Rocher-Ros, V, Jones, E V, Gulati, S, Coenen-Stass, A, Kozarewa, I, Lai, Z, Angell, H K, Opincar, L, Herbolsheimer, P & Kaufman, B 2020, ' Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA) : an open-label, multicentre, phase 1/2, basket study ', The Lancet. Oncology, vol. 21, no. 9, pp. 1155-1164 . https://doi.org/10.1016/S1470-2045(20)30324-7
BACKGROUND: Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in pati
Autor:
Fabienne Allias, Benoit You, Touria Hajri, Mojgan Devouassoux-Shisheboran, François Mallet, François Golfier, Jérôme Massardier, Sophie Patrier, Jonathan Lopez, Pierre-Adrien Bolze
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, 2020, 158, pp.785-793. ⟨10.1016/j.ygyno.2020.05.042⟩
Gynecologic Oncology, Elsevier, 2020, 158, pp.785-793. ⟨10.1016/j.ygyno.2020.05.042⟩
Gynecologic Oncology, 2020, 158, pp.785-793. ⟨10.1016/j.ygyno.2020.05.042⟩
Gynecologic Oncology, Elsevier, 2020, 158, pp.785-793. ⟨10.1016/j.ygyno.2020.05.042⟩
International audience; Objective: Using a transcriptional approach on tissue samples, we sought to identify predictive biomarkers of post molar malignant transformation, and of choriocarcinoma chemosensitivity to mono- (methotrexate or actinomycin D
Autor:
Philippe Follana, Pierre Combe, Eric Pujade-Lauraine, Alexandra Leary, Patrick Robelin, Gilles Freyer, Michel Fabbro, Nathalie Bonichon-Lamichhane, Christophe Desauw, Olivier Colomban, Christophe Louvet, Jean-Emmanuel Kurtz, Gwenael Ferron, M. Leheurteur, Annick Chevalier-Place, Benoit You, Gaëtan de Rauglaudre, Isabelle Ray-Coquard, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Florence Joly, Francesco Del Piano, Michel Tod
Publikováno v:
Clinical Cancer Research. 26:4625-4632
Purpose: In patients with ovarian cancer receiving neoadjuvant chemotherapy, the first-line treatment success will depend on both the tumor-primary chemosensitivity and the completeness of interval debulking surgery (IDS). The modeled CA-125 ELIMinat
Autor:
Mathilde Cancel, Oana Pop, Alain Lortholary, C.B. Levaché, Daniel Pissaloux, Magali Provansal, Elsa Kalbacher, Rémy Largillier, Amélie Anota, Audrey Lardy-Cleaud, Jérôme Meunier, Christophe Louvet, Anne-Claire Hardy-Bessard, Aurélie Houlier, Marie-Ange Mouret-Reynier, Fabien Brocard, Benoit You, Anne Floquet, Cyril Abdeddaim, Aude-Marie Savoye, Isabelle Ray-Coquard, Alain Zannetti, Laurence Venat-Bouvet, Isabelle Treilleux, Olivier Tredan, Jean-Sebastien Frenel
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, 2022, 164 (1), pp.18-26. ⟨10.1016/j.ygyno.2021.09.024⟩
Gynecologic Oncology, 2022, 164 (1), pp.18-26. ⟨10.1016/j.ygyno.2021.09.024⟩
Objective To evaluate the efficacy and safety of regorafenib versus tamoxifen in platinum-sensitive ovarian cancer biological recurrence, defined by CA-125 increase without radiological (RECIST criteria) or symptomatic evidence of progression. Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::442e0efad461a61c2ee12df093873312
https://hal.archives-ouvertes.fr/hal-03868128
https://hal.archives-ouvertes.fr/hal-03868128
Publikováno v:
SSRN Electronic Journal.
5530 Background: ICON8 phase III trial did not show improvement in PFS or OS with first-line weekly dose-dense chemotherapy in EOC. This analysis evaluated the impact of tumor intrinsic primary chemosensitivity (assessed with modeled CA-125 ELIMinati
Autor:
Michel Tod, Pierre-Adrien Bolze, Olivier Colomban, Rémi Tod, Benoit You, Michael J. Seckl, Gilles Freyer, R. Osborne, Kathleen Dekeister, Touria Hajri, François Golfier, Jean-Pierre Lotz, Jérôme Massardier
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:15-24
In a low-risk gestational trophoblastic neoplasia (GTN) treated with methotrexate (MTX), the modeled hCG (human chorionic gonadotropin) residual concentration (hCGres), calculated with NONMEM program® (NM) during the first 50 treatment days, is a pr